Viewing glioma as a regulatory network rather than a single-pathway disease, in a Vartholomatos et al. publication, CD71/TFRC emerges as a hub where hypoxia, inflammation, and therapy signals converge [85]. The gene discussed is TFRC; the disease is central nervous system cancer.